Abstract 644P
Background
Rivoceranib (Rivo) is a novel oral TKI that potently and selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR2). Selective inhibition of VEGFR2 has been shown to enhance the efficacy of chemotherapy. Herein, we present safety and efficacy results of the phase 1b portion of this study evaluating Rivo in patients (pts) with previously treated metastatic colorectal cancer.
Methods
In phase 1b of the study, a 3+3+3 dose-escalation was conducted to identify the recommended phase 2 dose (RP2D) of Rivo to be used in combination trifluridine/tipiracil. The phase 2 portion will evaluate the RP2D of Rivo PO QD (Days 1-28) in combination with trifluridine/tipiracil 35 mg/m2 PO BID (Days 1-5, 8-12 Q28 days).
Results
As of September 2022, 29 pts received treatment with Rivo. The median age was 54 yrs (range, 30-80), most pts were male (55.2%) and White (86.2%), ECOG PS was 0 (55.2%) or 1 (44.8%), and most pts received 3 (24.1%) or 4 (24.1%) prior lines of systemic therapy. Efficacy results at each dose level are summarized in the table. Dose limiting toxicities included myelosuppression, nausea, diarrhea, fatigue, asthenia, anorexia, proteinuria and arrythmia. No treatment-related deaths occurred. The patient who received the longest duration of treatment (>26 cycles) continues to receive treatment with rivoceranib.
Table: 644P
Efficacy results (intent-to-treat population)
300 mg (n=7) | 400 mg (n=7) | 500 mg (n=8) | 600 mg (n=7) | |
ORR, n (%) | 0 | 0 | 1 (12.5) | 0 |
BOR per RECIST v1.1 | ||||
PR, n (%) | 0 | 0 | 1 (12.5) | 0 |
SD, n (%) | 4 (57.1) | 5 (71.4) | 4 (50.0) | 1 (14.3) |
PD, n (%) | 2 (28.6) | 1 (14.3) | 3 (37.5) | 4 (57.1) |
NE, n (%) | 1 (14.3) | 1 (14.3) | 0 | 2 (28.6) |
mPFS, mo (95% CI) | 3.9 (0.9,8.3) | 4.2 (1.8,NE) | 3.6 (1.8,14.6) | 2.1 (1.2, NE) |
mOS, mo (95% CI) | 13.4 (1.9, 26.9) | 6.7 (3.1, NE) | 11.3 (3.3, NE) | 7.6 (5.2, NE) |
OS at 12 mo (95% CI) | 57.1 (17.2,83.7) | 42.9 (9.8,73.4) | 50.0 (15.2,77.5) | 33.3 (4.6,67.6) |
Conclusions
Rivo 400 mg PO QD is the RP2D to be used in combination with trifluridine/tipiracil 35 mg/m2 PO BID.
Clinical trial identification
NCT04073615.
Editorial acknowledgement
The Phillips Group Oncology Communications, Inc.
Legal entity responsible for the study
Elevar Therapeutics.
Funding
Elevar Therapeutics.
Disclosure
C.H. Park, X. Meng, S.H. Jang: Financial Interests, Personal, Full or part-time Employment: Elevar Therapeutics; Financial Interests, Personal, Stocks or ownership: Elevar Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11